Home LiteratureArticle Details
PMID: 6238120 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.

The Journal of experimental medicine ·Vol. 160 ·No. 5 ·1984-11-01 ·Pages 1558-78

Medof ME, Kinoshita T, Nussenzweig V

Abstract

Decay-accelerating factor (DAF), extracted from the stroma of human erythrocytes, was purified to homogeneity and incorporated into the membrane of sheep red cell complement intermediates, where its functional properties were analyzed. Incorporation of DAF into the cell membranes was temperature dependent, took place on pronase- or trypsin-treated erythrocytes, and did not depend on prior deposition of antibody, C1 or C4. Serum lipoproteins (high and low density) effectively inhibited DAF incorporation, but had no effect on the activity of DAF after its association with the cell membrane. The incorporated DAF could not be removed from the red cell surface by repeated washings in the presence of high salt concentration but was solubilized when the stroma were extracted with 0.1% Nonidet P-40. The presence of DAF in the membrane of EA did not affect the deposition of C1 and C4, but as few as 10(2) DAF molecules per cell profoundly inhibited the assembly of C3 and C5 convertases of both the classical and alternative pathways. The DAF inhibitory effect on EAC14 or EAC43 was not overcome by supplying an excess of C2 or factor B, but the alternative pathway C3 convertase could be assembled in the presence of Ni++, or nonphysiological concentrations of Mg++, which enhances the binding affinity of factor B for C3b. The DAF effect on EAC14 or EAC143 was entirely reversed by treating the cells with specific anti-DAF antibodies, showing that DAF did not alter the structure of C4b or C3b. Taken together, the experimental evidence suggests that DAF interacts directly with membrane-bound C3b or C4b and prevents subsequent uptake of C2 and factor B. DAF can function only within the cell membrane. Indeed, the decay dissociation of the C4b2a enzyme on DAF-containing sheep intermediates was not changed by varying the cell concentration. DAF-treated EA had no influence on the decay of nontreated EAC142 present in the same mixture. Moreover, the inhibitory activity of intact human erythrocytes on C4b2a was not blocked by antibodies to DAF, but was abolished by antibodies to the C3b/C4b receptor (CR1). When incorporated into the membrane of rabbit erythrocytes, human DAF inhibited their lysis by human complement. In conclusion, on the basis of these and previous results, it appears that DAF plays a central role in preventing the amplification of the complement cascade on host cell surfaces.(ABSTRACT TRUNCATED AT 400 WORDS)

MeSH Terms
Animals Carrier Proteins/pharmacology Complement Activating Enzymes/antagonists & inhibitors Complement Activation/drug effects Complement C3-C5 Convertases/antagonists & inhibitors Complement C3b Inactivator Proteins/blood,physiology Complement C4/metabolism Complement C4b Complement Inactivator Proteins Erythrocyte Membrane/enzymology,metabolism Glycoproteins Humans Magnesium/pharmacology Nickel/pharmacology Rabbits Receptors, Complement/physiology Receptors, Complement 3b Sheep
Chemicals
Carrier Proteins Complement C3b Inactivator Proteins Complement C4 Complement Inactivator Proteins Glycoproteins Receptors, Complement Receptors, Complement 3b Nickel Complement C4b Complement Activating Enzymes Complement C3-C5 Convertases Magnesium
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Medof M E
Kinoshita T
Nussenzweig V
References (35)
35 references, click to expand
  1. Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.
    Immunochemistry. 1966 Mar;3(2):111-35 PMID: 5960883
  2. Enharncement of the hemolytic activity of the second component of human complement by oxidation.
    J Exp Med. 1967 Dec 1;126(6):1013-25 PMID: 4964564
  3. Properties of highly purified human properdin.
    J Immunol. 1968 Jan;100(1):142-58 PMID: 4169693
  4. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  5. The reaction mechanism of human C5 in immune hemolysis.
    J Exp Med. 1970 Oct 1;132(4):775-93 PMID: 5508377
  6. Properdin factor D: characterization of its active site and isolation of the precursor form.
    J Exp Med. 1974 Feb 1;139(2):355-66 PMID: 4855753
  7. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
    J Exp Med. 1977 Jul 1;146(1):22-33 PMID: 559720
  8. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
    Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971-5 PMID: 273923
  9. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Proc Natl Acad Sci U S A. 1978 May;75(5):2416-20 PMID: 276881
  10. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867-71 PMID: 293688
  11. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator.
    Proc Natl Acad Sci U S A. 1979 Dec;76(12):6596-600 PMID: 293746
  12. Molecular biology and chemistry of the alternative pathway of complement.
    Adv Immunol. 1980;29:1-53 PMID: 6158260
  13. Purification of the human complement control protein C3b inactivator.
    Biochem J. 1980 Oct 1;191(1):173-82 PMID: 6451220
  14. Complement receptor is an inhibitor of the complement cascade.
    J Exp Med. 1981 May 1;153(5):1138-50 PMID: 6910481
  15. Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes.
    J Exp Med. 1981 Jun 1;153(6):1615-28 PMID: 7252422
  16. Defective immune-adherence (C3b) receptor on erythrocytes from patients with systemic lupus erythematosus.
    Lancet. 1981 Sep 5;2(8245):493-7 PMID: 6115248
  17. Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus.
    J Exp Med. 1982 May 1;155(5):1427-38 PMID: 6978375
  18. Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system.
    J Immunol. 1982 Jul;129(1):184-9 PMID: 6211481
  19. Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus.
    N Engl J Med. 1982 Oct 14;307(16):981-6 PMID: 7110302
  20. Generation of three different fragments of bound C3 with purified factor I or serum. I. Requirements for factor H vs CR1 cofactor activity.
    J Immunol. 1982 Nov;129(5):2051-60 PMID: 6214588
  21. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.
    J Immunol. 1982 Dec;129(6):2603-7 PMID: 6923908
  22. Regulation of glycophorin of complement activation via the alternative pathway.
    Biochem Biophys Res Commun. 1982 Sep 30;108(2):770-5 PMID: 7150322
  23. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
    J Exp Med. 1982 Dec 1;156(6):1739-54 PMID: 7175439
  24. Functional properties of membrane-associated complement receptor CR1.
    J Immunol. 1983 Apr;130(4):1876-80 PMID: 6220069
  25. Prevention of complement activation on the homologous cell membrane of nucleated cells as well as erythrocytes.
    Eur J Immunol. 1983 Apr;13(4):340-4 PMID: 6221932
  26. Decreased complement mediated binding of antibody/3H-dsDNA immune complexes to the red blood cells of patients with systemic lupus erythematosus, rheumatoid arthritis, and hematologic malignancies.
    Arthritis Rheum. 1983 Jun;26(6):736-44 PMID: 6860375
  27. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
    Eur J Immunol. 1983 Jun;13(6):465-70 PMID: 6222909
  28. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    J Immunol. 1983 Jul;131(1):403-8 PMID: 6602833
  29. Molecular titration of components of the classical complement pathway.
    Methods Enzymol. 1983;93:339-75 PMID: 6346014
  30. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
    Proc Natl Acad Sci U S A. 1983 Aug;80(16):5066-70 PMID: 6576376
  31. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria.
    Proc Natl Acad Sci U S A. 1983 Sep;80(17):5430-4 PMID: 6225118
  32. Comparison of binding characteristics of factors B and H to C3b on normal and paroxysmal nocturnal hemoglobinuria erythrocytes.
    J Immunol. 1983 Nov;131(5):2484-9 PMID: 6226743
  33. Species-specific inhibition by glycophorins of complement activation via the alternative pathway.
    Mol Immunol. 1983 Nov;20(11):1233-6 PMID: 6656770
  34. The covalent binding reaction of C3 and C4.
    Ann N Y Acad Sci. 1983;421:246-58 PMID: 6586101
  35. Control of the function of substrate-bound C4b-C3b by the complement receptor Cr1.
    J Exp Med. 1984 Jun 1;159(6):1669-85 PMID: 6233387
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
0022-1007
Published
1984-11-01
Pages
1558-78
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC2187498
Subset
IM
Grants
NIAID NIH HHS · AI 13224 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]